Table of Contents Author Guidelines Submit a Manuscript
Journal of Cancer Epidemiology
Volume 2015, Article ID 269304, 9 pages
http://dx.doi.org/10.1155/2015/269304
Research Article

Non-Small-Cell Lung Cancer Clinicopathologic Features and Survival Outcomes in Asian Pacific Islanders Residing in the United States: A SEER Analysis

1Department of Internal Medicine, Detroit Medical Center/Wayne State University, Detroit, MI 48201, USA
2Department of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
3Department of Internal Medicine, Lenox Hill Hospital, New York, NY 10065, USA
4Department of Pulmonology, Lenox Hill Hospital, New York, NY 10065, USA
5Department of Hematology-Oncology, Lenox Hill Hospital, New York, NY 10065, USA

Received 1 July 2014; Revised 27 November 2014; Accepted 27 November 2014

Academic Editor: P. Vineis

Copyright © 2015 Muhammad Saad Hamid et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Raz, S. L. Gomez, E. T. Chang et al., “Epidemiology of non-small cell lung cancer in Asian Americans: incidence patterns among six subgroups by nativity,” Journal of Thoracic Oncology, vol. 3, no. 12, pp. 1391–1397, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. A. K. Ganti, S. P. Subbiah, A. Kessinger, W. I. Gonsalves, P. T. Silberstein, and F. R. Loberiza Jr., “Association between race and survival of patients with non-small-cell lung cancer in the united states veterans affairs population,” Clinical Lung Cancer, vol. 15, no. 2, pp. 152–158, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. C. R. Mulligan, A. D. Meram, C. D. Proctor, H. Wu, K. Zhu, and A. J. Marrogi, “Unlimited access to care: effect on racial disparity and prognostic factors in lung cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 1, pp. 25–31, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J. P. Wisnivesky, T. McGinn, C. Henschke, P. Hebert, M. C. Iannuzzi, and E. A. Halm, “Ethnic disparities in the treatment of stage I non-small cell lung cancer,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 10, pp. 1158–1163, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. “SEER Stat Fact Sheets: Lung and Bronchus Cancer,” Surveillance, Epidemiology, and End Result, 2014, http://seer.cancer.gov/statfacts/html/lungb.html.
  6. A. M. Saeed, R. Toonkel, M. K. Glassberg et al., “The influence of hispanic ethnicity on nonsmall cell lung cancer histology and patient survival: an analysis of the survival, epidemiology, and end results database,” Cancer, vol. 118, no. 18, pp. 4495–4501, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. S.-H. I. Ou, J. A. Zell, A. Ziogas, and H. Anton-Culver, “Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003,” Cancer, vol. 110, no. 7, pp. 1532–1541, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. E. T. Chang, S. J. Shema, H. A. Wakelee, C. A. Clarke, and S. L. Gomez, “Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California,” Cancer Epidemiology, Biomarkers & Prevention, vol. 18, no. 8, pp. 2248–2255, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. “Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity,” OncoLink: the Web's first cancer resource, University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pa, USA, 1994–2014, http://www.oncolink.org/conferences/article.cfm?c=3&s=48&ss=268&id=1761.
  10. A. G. Schwartz, M. L. Cote, A. S. Wenzlaff, S. Land, and C. I. Amos, “Racial differences in the association between SNPs on 15q25.1, smoking behavior, and risk of non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 4, no. 10, pp. 1195–1201, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. A. K. Ferketich, J. C. Niland, R. Mamet et al., “Smoking status and survival in the national comprehensive cancer network non-small cell lung cancer cohort,” Cancer, vol. 119, no. 4, pp. 847–853, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S.-H. I. Ou, A. Ziogas, and J. A. Zell, “Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status,” Journal of Thoracic Oncology, vol. 4, no. 9, pp. 1083–1093, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. L. Zheng, L. Enewold, S. H. Zahm et al., “Lung cancer survival among black and white patients in an equal access health system,” Cancer Epidemiology, Biomarkers & Prevention, vol. 21, no. 10, pp. 1841–1847, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. K. Cetin, D. S. Ettinger, Y.-J. Hei, and C. D. O'Malley, “Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the surveillance, epidemiology and end results program,” Clinical Epidemiology, vol. 3, no. 1, pp. 139–148, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. M. L. Wong, C. A. Clarke, J. Yang, J. Hwang, R. A. Hiatt, and S. Wang, “Incidence of non-small-cell lung cancer among California hispanics according to neighborhood socioeconomic status,” The Journal of Thoracic Oncology, vol. 8, no. 3, pp. 287–294, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. L. R. Shugarman, K. MacK, M. E. S. Sorbero et al., “Race and sex differences in the receipt of timely and appropriate lung cancer treatment,” Medical Care, vol. 47, no. 7, pp. 774–781, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. B. Goulart, C. Reyes, C. Fedorenko et al., “Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer,” Journal of Oncology Practice, vol. 9, no. 1, pp. 42–50, 2013. View at Google Scholar
  18. D. Hardy, C.-C. Liu, R. Xia et al., “Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer,” Cancer, vol. 115, no. 10, pp. 2199–2211, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. L. L. Zullig, W. R. Carpenter, D. T. Provenzale et al., “The association of race with timeliness of care and survival among Veterans Affairs health care system patients with late-stage non-small cell lung cancer,” Cancer Management and Research, vol. 5, no. 1, pp. 157–163, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. A. S. Bryant and R. J. Cerfolio, “Impact of race on outcomes of patients with non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 3, no. 7, pp. 711–715, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. A.-P. Meert, B. Martin, P. Delmotte et al., “The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis,” European Respiratory Journal, vol. 20, no. 4, pp. 975–981, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. A. F. Gazdar, “Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors,” Oncogene, vol. 28, no. 1, pp. S24–S31, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. P. A. Jänne, B. E. Johnson, T. Lynch et al., “Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors,” Clinical Cancer Research, vol. 12, no. 14, pp. 4416s–4420s, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. M. Nomura, H. Shigmatsu, L. Li et al., “Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers,” PLoS Medicine, vol. 4, no. 4, article e125, 2007. View at Google Scholar
  25. J. Bauml, R. Mick, Y. Zhang et al., “Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?” Lung Cancer, vol. 81, no. 3, pp. 347–353, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. M. L. Cote, R. Haddad, D. J. Edwards et al., “Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 6, no. 3, pp. 627–630, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. R. Ng, B. Hasan, N. Mittmann et al., “Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer—a report of the working group on economic analysis, and the lung disease site group, National Cancer Institute of Canada Clinical Trials Group,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2256–2261, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. K. Kelly, K. Chansky, L. E. Gaspar et al., “Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023,” Journal of Clinical Oncology, vol. 26, no. 15, pp. 2450–2456, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. G. Giaccone, R. S. Herbst, C. Manegold et al., “Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 777–784, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. R. S. Herbst, G. Giaccone, J. H. Schiller et al., “Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 785–794, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. N. Thatcher, A. Chang, P. Parikh et al., “Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer),” The Lancet, vol. 366, no. 9496, pp. 1527–1537, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus